The anti-VLA-4 antibody natalizumab induces erythroblastaemia in the majority of the treated patients with multiple sclerosis

Multiple Sclerosis Journal

Volumn 20, Issue 9, 2014, Pages 1269-1272

  Robier, Christoph ^a   Amouzadeh Ghadikolai, Omid ^a   Bregant, Claudia ^a   Diez, Josef ^a   Melinz, Klaus ^a   Neubauer, Manfred ^a   Quasthoff, Stefan ^a  

^a Central Laboratory Hospital of the Brothers of St John of God   (Austria)

Author keywords

Erythroblastaemia; erythroblasts; multiple sclerosis; natalizumab

Indexed keywords

BETA INTERFERON; NATALIZUMAB; IMMUNOLOGIC FACTOR; VERY LATE ACTIVATION ANTIGEN 4;

ADULT; ARTICLE; BLOOD SMEAR; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROBLASTEMIA; ERYTHROCYTE DISORDER; FEMALE; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; AUSTRIA; BLOOD; CASE CONTROL STUDY; CHEMICALLY INDUCED; DRUG EFFECTS; ERYTHROBLAST; HEMATOLOGIC DISEASE; IMMUNOLOGY; MIDDLE AGED; PREVALENCE; RISK FACTOR; YOUNG ADULT; CELL MATURATION; DRUG SAFETY; ERYTHROCYTE;

ADULT; AUSTRIA; CASE-CONTROL STUDIES; ERYTHROBLASTS; FEMALE; HEMATOLOGIC DISEASES; HUMANS; IMMUNOLOGIC FACTORS; INTEGRIN ALPHA4BETA1; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NATALIZUMAB; PREVALENCE; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904207529     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514521307     Document Type: Article

References (10)

1. Tavassoli M. Erythroblastemia. West J Med. 1975 ; 122: 194-198
2. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New Engl J Med. 2006 ; 354: 899-910
3. Ransohoff RM. Natalizumab for multiple sclerosis. New Engl J Med. 2007 ; 356: 2622-2629 (Pubitemid 46961007)
4. Hamamura K, Matsuda H, Takeuchi Y, et al. A critical role of VLA-4 in erythropoiesis in vivo. Blood. 1996 ; 87: 2513-2517 (Pubitemid 26086897)
5. Bonig H, Wundes A, Chang K, et al. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood. 2008 ; 111: 3439-3441
6. Zohren F, Toutzaris D, Klärner V, et al. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood. 2008 ; 111: 3893-3895
7. Jing D, Oelschlaegel U, Ordemann R, et al. CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. Bone Marrow Transplant. 2010 ; 45: 1489-1496
8. Saure C, Warnke C, Zohren F, et al. Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors. Arch Neurol. 2011 ; 68: 1428-1431
9. Papayannopoulou T, Nakamoto B. Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin. Proc Natl Acad Sci. 1993 ; 90: 9374-9378 (Pubitemid 23315786)
10. Rispens T, Vennegoor A, Wolbink GJ, et al. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped. Mult Scler. 2012 ; 18: 899-901